Figures & data
Figure 1. Median survival of 1272 cancer patients with IL-6 serum levels above various chosen cut-off values in 24 dichotomized studies (26 cohorts). Both x and y parameters have been have log-transformed in the graph. Sample size was used to weigh the studies. The median survival at chosen cut-off points was inversely correlated to the minimum IL-6 serum level at this cut-off, both when sample size was used to weigh the studies (p < 0.001) and also when the cohorts were not weighted (p < 0.005). Numbers indicate series as listed in .
![Figure 1. Median survival of 1272 cancer patients with IL-6 serum levels above various chosen cut-off values in 24 dichotomized studies (26 cohorts). Both x and y parameters have been have log-transformed in the graph. Sample size was used to weigh the studies. The median survival at chosen cut-off points was inversely correlated to the minimum IL-6 serum level at this cut-off, both when sample size was used to weigh the studies (p < 0.001) and also when the cohorts were not weighted (p < 0.005). Numbers indicate series as listed in Table 2.](/cms/asset/a343c248-4f4e-4d4a-99c0-426b88230bb5/koni_a_1093722_f0001_oc.gif)
Table 1. Summary of clinical series with cancer patients that reported the serum level of IL-6 and its potential association with survival.
Table 2. In 24 dichotomized studies (26 cohorts) comprising 1272 patients, the median survival was reported for patients in whom the IL-6 serum level was higher than the chosen cut-off value. References, primary cancer type, number of patients, cut-off for IL-6 serum level (pg/mL) and median survival are given in the table.